Fryden A - Search Results

1

Serum hepatitis C virus RNA levels in chronic hepatitis C--importance for outcome of interferon alfa-2b treatment.

Yun ZB, Reichard O, Chen M, Lundeberg J, Norkrans G, Fryden A, Sönnerborg A, Weiland O. Yun ZB, et al. Among authors: fryden a. Scand J Infect Dis. 1994;26(3):263-70. doi: 10.3109/00365549409011794. Scand J Infect Dis. 1994. PMID: 7939425

2

High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks.

Reichard O, Foberg U, Frydén A, Mattsson L, Norkrans G, Sönnerborg A, Wejstål R, Yun ZB, Weiland O. Reichard O, et al. Among authors: fryden a. Hepatology. 1994 Feb;19(2):280-5. Hepatology. 1994. PMID: 7507462 Clinical Trial.

3

Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course.

Reichard O, Glaumann H, Norkrans G, Wejstål R, Fryden A, Schvarcz R, Weiland O. Reichard O, et al. Among authors: fryden a. Liver. 1994 Aug;14(4):169-74. doi: 10.1111/j.1600-0676.1994.tb00070.x. Liver. 1994. PMID: 7526108

4

Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment.

Reichard O, Glaumann H, Frydén A, Norkrans G, Schvarcz R, Sönnerborg A, Yun ZB, Weiland O. Reichard O, et al. Among authors: fryden a. Hepatology. 1995 Apr;21(4):918-22. Hepatology. 1995. PMID: 7705800

5

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.

Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Reichard O, et al. Among authors: fryden a. Lancet. 1998 Jan 10;351(9096):83-7. doi: 10.1016/s0140-6736(97)06088-1. Lancet. 1998. PMID: 9439491 Clinical Trial.

6

Comparison of 3 quantitative HCV RNA assays--accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C.

Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Reichard O, et al. Among authors: fryden a. Scand J Infect Dis. 1998;30(5):441-6. doi: 10.1080/00365549850161395. Scand J Infect Dis. 1998. PMID: 10066040

7

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon.

Reichard O, Glaumann H, Frydén A, Norkrans G, Wejstål R, Weiland O. Reichard O, et al. Among authors: fryden a. J Hepatol. 1999 May;30(5):783-7. doi: 10.1016/s0168-8278(99)80129-9. J Hepatol. 1999. PMID: 10365802 Clinical Trial.

8

Influence of pre-treatment factors on outcome of interferon-alpha treatment of patients with chronic hepatitis C.

Weiland O, Braconier JH, Frydén A, Norkrans G, Reichard O, Uhnoo I. Weiland O, et al. Among authors: fryden a. Scand J Infect Dis. 1999;31(2):115-8. doi: 10.1080/003655499750006119. Scand J Infect Dis. 1999. PMID: 10447316 Clinical Trial.

9

Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis.

Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstål R, Frydén A. Schvarcz R, et al. Among authors: fryden a. Liver. 1991 Feb;11(1):30-8. doi: 10.1111/j.1600-0676.1991.tb00487.x. Liver. 1991. PMID: 1646369 Clinical Trial.

10

Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders.

Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstål R, Frydén A. Schvarcz R, et al. Among authors: fryden a. Scand J Infect Dis. 1991;23(4):413-20. doi: 10.3109/00365549109075088. Scand J Infect Dis. 1991. PMID: 1957127 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

96 results

Search Page

Filters